Advertisement
Research Article Free access | 10.1172/JCI119302
Department of Medicine, The University of California, San Francisco 94143, USA. crb@itsa.ucsf.edu
Find articles by Brown, C. in: JCI | PubMed | Google Scholar
Department of Medicine, The University of California, San Francisco 94143, USA. crb@itsa.ucsf.edu
Find articles by Hong-Brown, L. in: JCI | PubMed | Google Scholar
Department of Medicine, The University of California, San Francisco 94143, USA. crb@itsa.ucsf.edu
Find articles by Welch, W. in: JCI | PubMed | Google Scholar
Published March 15, 1997 - More info
Recently, we found that different low molecular weight compounds, all known to stabilize proteins in their native conformation, are effective in correcting the temperature-sensitive protein folding defect associated with the deltaF508 cystic fibrosis transmembrane regulator (CFTR) protein. Here we examined whether the folding of other proteins which exhibit temperature-sensitive folding defects also could be corrected via a similar strategy. Cell lines expressing temperature-sensitive mutants of the tumor suppressor protein p53, the viral oncogene protein pp60src, or a ubiquitin activating enzyme E1, were incubated at the nonpermissive temperature (39.5 degrees C) in the presence of glycerol, trimethylamine N-oxide or deuterated water. In each case, the cells exhibited phenotypes similar to those observed when the cells were incubated at the permissive temperature (32.5 degrees C), indicative that the particular protein folding defect had been corrected. These observations, coupled with our earlier work and much older studies in yeast and bacteria, indicate that protein stabilizing agents are effective in vivo for correcting protein folding abnormalities. We suggest that this type of approach may prove to be useful for correcting certain protein folding abnormalities associated with human diseases.